Cartesian Therapeutics (RNAC) Interest Expenses (2015 - 2026)

Cartesian Therapeutics (RNAC) has reported Interest Expenses for 12 consecutive years, with $1.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Interest Expenses rose 268.77% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $3.6 million (down 97.27% YoY), while the FY2025 annual figure was $296.9 million, up 19.79% from the prior year.
• Interest Expenses climbed to $1.2 million in Q1 2026 per RNAC's latest filing, from $1.1 million in the prior quarter.
• Across five years, Interest Expenses topped out at $130.5 million in Q4 2023 and bottomed at $317000.0 in Q1 2025.
• Historically, Interest Expenses has averaged $13.2 million across 5 years, with a median of $1.2 million in 2026.
• Annual changes were most pronounced in 2023 — Interest Expenses surged 7874.39% — and 2024, when it tumbled 99.23%.
• Cartesian Therapeutics' Interest Expenses stood at $1.6 million in 2022, then soared by 7874.39% to $130.5 million in 2023, then sank by 99.23% to $1.0 million in 2024, then advanced by 12.27% to $1.1 million in 2025, then advanced by 3.0% to $1.2 million in 2026.
• Business Quant data shows RNAC's Interest Expenses at $1.2 million in Q1 2026, $1.1 million in Q4 2025, and $5.1 million in Q3 2025.